#33 Bisphosphonates: Forever or Five Years and Stop?
CLINICAL QUESTION
Can patients with osteoporosis who have taken bisphosphonates for five years discontinue treatment without increasing future fracture risk?
BOTTOM LINE
Available evidence suggests that after five years of treatment, discontinuation of bisphosphonates carries little to no increased future fracture risk. Choosing appropriate patients to continue therapy beyond five years and determining when or if to reinitiate therapy in those discontinued, remains uncertain.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
FLEX1 : Randomized controlled trial (RCT) of 1,099 post-menopausal women with osteoporosis (mean age 73, 60% with previous fracture) previously on alendronate for 4-5 years. Patients were randomized to alendronate 5 mg, 10 mg, or placebo. After five additional years:
- Bone mineral density (BMD) measurements in the placebo group were lower than the alendronate group.
- Total non-vertebral fractures and total vertebral fractures were not statistically different.
- In only one outcome subgroup, total clinical vertebral fractures, alendronate statistically significantly lowered fractures (2.4% versus 5.3% placebo). Number needed to treat is 36 for continuing alendronate.
- Although patients with lower BMD or previous fractures had a higher risk of fractures, there was no statistically significant benefit seen in these subgroups.
- Two smaller flawed studies examining discontinuation of bisphosphonates (without randomization) also found those discontinuing had: (1) Lower BMDs,3,4 (2) Residual fracture protection, 4 and (3) No statistical difference in fracture rates compared to those continuing therapy.3
- Interpreting osteoporosis studies presents many challenges:
- Significant heterogeneity among populations studied, how BMD is reported and the classifications of fractures.
- Large variability in BMD measurements make interpretation difficult. 5
- Many studies are not designed to evaluate symptomatic fractures, the clinically most important outcome.
- Observational studies demonstrate potential adverse events with bisphosphonate (gastrointestinal, bone). 6,7
- No consensus exists regarding optimal duration of bisphosphonate therapy.
- Some suggest stopping bisphosphonates after five years in lower risk patients, such as those without previous fractures.8
- This subgroup selection is not based on RCT evidence.
- Some suggest stopping bisphosphonates after five years in lower risk patients, such as those without previous fractures.8
Latest Tools for Practice
#370 Antibiotics or no antibiotics for acute diverticulitis, that is the question!
Do antibiotics change clinical outcomes for patients with acute uncomplicated diverticulitis?
#369 Remind me, do medications that target brain amyloid improve my dementia?
Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment or Alzheimer’s dementia?
#368 Sodium Restriction in Heart Failure: Beneficial or pouring salt in the wound?
Does sodium restriction improve outcomes in patients with chronic heart failure?
